Integrated BioPharma Reports Results; Appoints Head of Operations at MDC

What Happened
Integrated BioPharma, Inc. (INBP) filed a Form 8-K on August 20, 2026 announcing results of operations and financial condition via a press release dated August 20, 2026. The company also disclosed the appointment of Michael Richtmyer as Head of Operations of Manhattan Drug Company, Inc. (MDC), a wholly owned subsidiary of Integrated BioPharma.

Key Details

• Filing date: August 20, 2026; press release attached as Exhibit 99.1.
• Item 2.02: the 8-K reports results of operations and financial condition (press release contains the detailed financial information).
• Item 8.01: Michael Richtmyer named Head of Operations for MDC (effective as announced in the August 20, 2026 press release).
• MDC is a wholly owned subsidiary of Integrated BioPharma.

Why It Matters
This filing provides investors with the company’s latest operational and financial update (see the attached press release for the specific figures and context). The appointment of a new Head of Operations at MDC is a leadership change at a consolidated subsidiary that could affect execution of MDC’s operations and integration with the parent company. Investors should review Exhibit 99.1 (the August 20, 2026 press release) for the complete financial details and any management commentary.